Digitizing the Value Chain in Life Sciences
The life sciences industry is in the midst of a transformation bringing both opportunities and challenges. The industry is getting a boost from aging demographics, a growing middle class in emerging markets, increasing demand driven by growing global prosperity, and remarkable advances in science and technology. But at the same time, CEOs feel pressure to deliver short-term returns, navigate complex regulations and remain competitive in a quickly evolving marketplace where government health plans are trying to cut costs.
Innovation has been the lifeblood of this industry’s growth and response to market disruption. However, for life sciences organizations to achieve shareholder returns, innovation strategies must also be accompanied by cost-transformation strategies. We refer to this as the industry’s dual challenge: innovate to grow and reduce costs.
At CSC Life Sciences, we are committed to helping our clients solve this dual challenge by implementing Capital-Efficient Innovation strategies. While innovation in life sciences often focuses on R&D productivity, we also see capital-efficient innovation opportunities for:
- Leveraging Regulatory Information Management across the enterprise for greater business value
- Enhancing the supply chain’s flexibility, responsiveness and transparency
At CSC, we focus on delivering solutions that address the following areas of greatest innovation opportunity:
Life sciences companies are under pressure to balance innovation with cost-cutting measures — across the enterprise — while ensuring that the drugs they bring to market are managed in a patient-centric way. The flow of information from research and development (R&D) to the health authority, and then from the affiliate ultimately to the patient, requires a new regulatory information management (RIM) plan. With the complex dynamics in play, life sciences companies must adopt a big-picture RIM strategy that drives smarter, faster and lower-cost decision making.
A combination of regulations and market-based challenges, including dwindling pipelines and falling revenues, are forcing life sciences companies to improve visibility and transparency in the supply chain. They need higher-quality data and a robust technology platform to support underlying compliance and risk-management requirements. Our Digital Supply Chain solution is a comprehensive suite of offerings that enables the enterprise to manage multiple product lines, across multiple distribution channels, in multiple regions and with multiple collaborative partners — all from a centralized location.
Leverage CSC’s unique combination of software, consulting, business process services and application modernization to solve the upcoming Identification of Medicinal Products (IDMP) requirements and build a controlled product lifecycle master data environment. IDMP requires structuring information previously only found in narrative documentation, and integrating knowledge from manufacturing, logistics, quality, safety and clinical, as well as regulatory. This challenge requires concerted effort and significant change to databases and processes to manage data around pharmaceutical products.
Life sciences companies are under pressure to do more with less. Regulatory authorities want more data, more rapidly, and companies struggle to find the time, resources and expertise to respond to compliance demands while maneuvering through the peaks and troughs of product submissions. Each stage of the process requires unique skills at the right time, making it next to impossible to manage resources as and when required for the full submission life cycle. Life sciences companies urgently need options. They need a reliable, scalable team of subject matter experts to turn to, paired with a flexible yet robust technology infrastructure.
CSC brings a full suite of Content Management, Collaboration and Authoring tools to our clients that span the full life cycle through to Publishing, Submissions and Tracking.
For more information, please contact us.